| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myelomonocytic, Chronic | 8 | 2022 | 426 | 2.450 |
Why?
|
| Myelodysplastic Syndromes | 21 | 2022 | 2979 | 2.340 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 3 | 2022 | 33 | 1.860 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 4 | 2022 | 113 | 1.440 |
Why?
|
| Histones | 9 | 2013 | 1466 | 0.850 |
Why?
|
| Dioxygenases | 1 | 2022 | 159 | 0.800 |
Why?
|
| Antigens, CD34 | 5 | 2019 | 593 | 0.670 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2015 | 612 | 0.670 |
Why?
|
| Toll-Like Receptors | 3 | 2014 | 174 | 0.640 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2015 | 234 | 0.590 |
Why?
|
| Pyrroles | 2 | 2010 | 576 | 0.560 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 85 | 0.510 |
Why?
|
| Autophagy | 2 | 2010 | 927 | 0.480 |
Why?
|
| Erythropoiesis | 1 | 2014 | 74 | 0.480 |
Why?
|
| Epigenesis, Genetic | 5 | 2016 | 1399 | 0.450 |
Why?
|
| Gene Expression | 5 | 2016 | 3570 | 0.430 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 278 | 0.430 |
Why?
|
| Azacitidine | 7 | 2022 | 1149 | 0.420 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2013 | 249 | 0.410 |
Why?
|
| Immunity, Innate | 2 | 2013 | 677 | 0.410 |
Why?
|
| Down-Regulation | 3 | 2016 | 2074 | 0.400 |
Why?
|
| Lysine | 1 | 2013 | 422 | 0.380 |
Why?
|
| Chromosome Mapping | 3 | 2013 | 1471 | 0.380 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 1005 | 0.380 |
Why?
|
| Leukemia | 4 | 2015 | 1635 | 0.370 |
Why?
|
| NF-kappa B | 2 | 2014 | 1549 | 0.360 |
Why?
|
| Apoptosis | 5 | 2017 | 7591 | 0.340 |
Why?
|
| CDC2-CDC28 Kinases | 4 | 2005 | 129 | 0.340 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 4821 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2018 | 1242 | 0.330 |
Why?
|
| Transcriptome | 3 | 2022 | 1859 | 0.320 |
Why?
|
| DNA Methylation | 8 | 2016 | 2669 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2017 | 6915 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8873 | 0.300 |
Why?
|
| Cyclin E | 4 | 2005 | 267 | 0.300 |
Why?
|
| Coiled Bodies | 3 | 2003 | 8 | 0.300 |
Why?
|
| S Phase | 5 | 2005 | 281 | 0.270 |
Why?
|
| Hydroxamic Acids | 5 | 2013 | 442 | 0.270 |
Why?
|
| Hematopoiesis | 3 | 2018 | 560 | 0.250 |
Why?
|
| Nuclear Proteins | 6 | 2015 | 3343 | 0.240 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2003 | 311 | 0.240 |
Why?
|
| Cell Cycle Proteins | 5 | 2005 | 2045 | 0.240 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2015 | 560 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2014 | 2947 | 0.220 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2014 | 155 | 0.220 |
Why?
|
| Proteins | 3 | 2011 | 1963 | 0.210 |
Why?
|
| Mutation | 12 | 2022 | 15179 | 0.210 |
Why?
|
| Loss of Function Mutation | 1 | 2022 | 132 | 0.200 |
Why?
|
| Myelopoiesis | 1 | 2021 | 31 | 0.190 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Models, Biological | 3 | 2014 | 3254 | 0.190 |
Why?
|
| Thrombocytosis | 1 | 2021 | 121 | 0.180 |
Why?
|
| Blood Cells | 2 | 2018 | 127 | 0.180 |
Why?
|
| Drug Synergism | 4 | 2010 | 1313 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 5 | 2015 | 3101 | 0.180 |
Why?
|
| Humans | 42 | 2022 | 261506 | 0.180 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2021 | 114 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2021 | 250 | 0.180 |
Why?
|
| Cell Line, Tumor | 10 | 2017 | 14551 | 0.170 |
Why?
|
| Gene Expression Profiling | 5 | 2022 | 5159 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 2488 | 0.170 |
Why?
|
| Up-Regulation | 3 | 2021 | 2450 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 3639 | 0.170 |
Why?
|
| Cell Differentiation | 3 | 2015 | 4078 | 0.170 |
Why?
|
| Animals | 10 | 2022 | 59536 | 0.170 |
Why?
|
| Base Sequence | 6 | 2013 | 4917 | 0.160 |
Why?
|
| Mice | 5 | 2022 | 34495 | 0.160 |
Why?
|
| Genome | 1 | 2022 | 672 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 6 | 2017 | 5395 | 0.150 |
Why?
|
| IMP Dehydrogenase | 1 | 2017 | 27 | 0.150 |
Why?
|
| Interleukin-8 | 3 | 2016 | 519 | 0.150 |
Why?
|
| Gene Expression Regulation | 5 | 2014 | 4053 | 0.150 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Imidazoles | 1 | 2022 | 999 | 0.140 |
Why?
|
| Molecular Sequence Data | 6 | 2013 | 6089 | 0.140 |
Why?
|
| Amino Acid Sequence | 5 | 2013 | 4233 | 0.140 |
Why?
|
| Prognosis | 11 | 2021 | 21713 | 0.140 |
Why?
|
| HL-60 Cells | 3 | 2010 | 302 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 1217 | 0.130 |
Why?
|
| Phosphoproteins | 1 | 2021 | 1152 | 0.130 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 32 | 0.130 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2016 | 160 | 0.130 |
Why?
|
| Benzamides | 2 | 2010 | 1832 | 0.130 |
Why?
|
| Bone Marrow | 4 | 2019 | 2358 | 0.130 |
Why?
|
| Indoles | 2 | 2010 | 1009 | 0.130 |
Why?
|
| Cell Proliferation | 5 | 2017 | 7226 | 0.120 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2014 | 24 | 0.120 |
Why?
|
| Chromosome Inversion | 1 | 2015 | 182 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 2359 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 1165 | 0.120 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 27 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2013 | 2796 | 0.120 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2013 | 8 | 0.120 |
Why?
|
| Signal Transduction | 6 | 2014 | 11965 | 0.120 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2013 | 30 | 0.120 |
Why?
|
| K562 Cells | 1 | 2014 | 338 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 78 | 0.110 |
Why?
|
| Gene Order | 1 | 2013 | 111 | 0.110 |
Why?
|
| Erythroid Cells | 1 | 2013 | 49 | 0.110 |
Why?
|
| G1 Phase | 3 | 2005 | 285 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 87 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2014 | 1764 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2013 | 1664 | 0.110 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 365 | 0.110 |
Why?
|
| Multigene Family | 1 | 2014 | 425 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 1439 | 0.110 |
Why?
|
| Leukemia, B-Cell | 1 | 2013 | 117 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 943 | 0.110 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2011 | 29 | 0.100 |
Why?
|
| Telomere | 1 | 2015 | 505 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2016 | 6150 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 709 | 0.100 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 29902 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 644 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 15862 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 1121 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 336 | 0.100 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2010 | 37 | 0.100 |
Why?
|
| Isothiocyanates | 1 | 2010 | 44 | 0.090 |
Why?
|
| Oncogenes | 1 | 2013 | 673 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 383 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 252 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2005 | 249 | 0.090 |
Why?
|
| CTLA-4 Antigen | 1 | 2013 | 657 | 0.090 |
Why?
|
| Methylation | 1 | 2011 | 597 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 622 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3230 | 0.080 |
Why?
|
| ras Proteins | 1 | 2013 | 770 | 0.080 |
Why?
|
| Aged | 12 | 2021 | 70117 | 0.080 |
Why?
|
| Middle Aged | 13 | 2021 | 86204 | 0.080 |
Why?
|
| Amino Acid Motifs | 3 | 2005 | 392 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3552 | 0.080 |
Why?
|
| Retina | 1 | 2011 | 532 | 0.080 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 801 | 0.080 |
Why?
|
| Pyrimidines | 2 | 2010 | 3518 | 0.080 |
Why?
|
| Cytarabine | 1 | 2014 | 1973 | 0.080 |
Why?
|
| Male | 15 | 2021 | 123000 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 1048 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 15193 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2013 | 3536 | 0.070 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1026 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2014 | 1824 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 669 | 0.070 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 1022 | 0.070 |
Why?
|
| Cell Cycle | 3 | 2017 | 2084 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2011 | 1152 | 0.070 |
Why?
|
| Female | 15 | 2021 | 141928 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 1960 | 0.070 |
Why?
|
| CpG Islands | 1 | 2008 | 633 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2013 | 2819 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 1350 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 5178 | 0.070 |
Why?
|
| Adult | 10 | 2016 | 77950 | 0.060 |
Why?
|
| DNA | 1 | 2013 | 2693 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 14289 | 0.060 |
Why?
|
| Peptide Synthases | 1 | 2003 | 7 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1493 | 0.060 |
Why?
|
| Cullin Proteins | 1 | 2003 | 41 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 3154 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 1487 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2018 | 668 | 0.060 |
Why?
|
| G2 Phase | 1 | 2003 | 206 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 5047 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 14889 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 503 | 0.050 |
Why?
|
| Luciferases | 1 | 2003 | 445 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 611 | 0.050 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 10331 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 268 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 997 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2005 | 1620 | 0.050 |
Why?
|
| Plasmids | 1 | 2003 | 837 | 0.050 |
Why?
|
| RNA Splicing Factors | 1 | 2021 | 153 | 0.050 |
Why?
|
| Survival Rate | 4 | 2016 | 12221 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 769 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2019 | 39 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2021 | 1732 | 0.040 |
Why?
|
| Genome, Human | 1 | 2008 | 1869 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2003 | 1682 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2013 | 837 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 2390 | 0.040 |
Why?
|
| Sex Factors | 2 | 2013 | 2139 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2003 | 4804 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2018 | 93 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 3203 | 0.040 |
Why?
|
| Guanine | 1 | 2017 | 151 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1070 | 0.040 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2016 | 24 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2018 | 269 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 6682 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6207 | 0.030 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2015 | 88 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 452 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2019 | 874 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2003 | 2022 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 1073 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2015 | 123 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 245 | 0.030 |
Why?
|
| Rats | 1 | 2003 | 6086 | 0.030 |
Why?
|
| Receptor, EphA5 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 842 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 42 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2016 | 6100 | 0.030 |
Why?
|
| Haploinsufficiency | 1 | 2015 | 294 | 0.030 |
Why?
|
| Receptor, Notch3 | 1 | 2013 | 31 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2013 | 85 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2015 | 370 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2013 | 101 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 490 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2013 | 122 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 2003 | 549 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2011 | 39 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2013 | 684 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2013 | 264 | 0.030 |
Why?
|
| Rhodopsin | 1 | 2011 | 70 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2013 | 9180 | 0.030 |
Why?
|
| Consanguinity | 1 | 2011 | 114 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 10001 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 43 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2014 | 583 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 545 | 0.020 |
Why?
|
| U937 Cells | 1 | 2010 | 171 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 1163 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 838 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 146 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 305 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 650 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2013 | 9244 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 2522 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 1879 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2011 | 263 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2003 | 5270 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 392 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 463 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 4938 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 534 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2003 | 1643 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 717 | 0.020 |
Why?
|
| Tretinoin | 1 | 2011 | 623 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 6295 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1328 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1399 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 1890 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 1479 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 1299 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 1294 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 3033 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 2283 | 0.020 |
Why?
|
| Antioxidants | 1 | 2010 | 507 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 6942 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 17523 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 4298 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1331 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Exome | 1 | 2011 | 1239 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2330 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.020 |
Why?
|
| Cell Line | 2 | 2003 | 5114 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 2483 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 2437 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 987 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 2010 | 941 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 21445 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8865 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2005 | 162 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2008 | 793 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 3045 | 0.010 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2003 | 42 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 4109 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 189 | 0.010 |
Why?
|
| Adolescent | 2 | 2014 | 31252 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 629 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2003 | 205 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2016 | 32848 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 2291 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2003 | 129 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 292 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 869 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2265 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 2508 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 1213 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2003 | 435 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2000 | 329 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 3869 | 0.010 |
Why?
|
| Chromatin | 1 | 2005 | 942 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4549 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2000 | 179 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 5539 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2000 | 327 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 1062 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 2927 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 3438 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 13310 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 6550 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 5637 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 37905 | 0.010 |
Why?
|